Hepatocellular Carcinoma (HCC) Cell Models for Research

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, accounting for approximately 90% of all liver cancer cases. According to the World Health Organization (WHO), liver cancer is the sixth most commonly diagnosed cancer and the third leading cause of cancer-related death worldwide, with an estimated 905,677 new cases and 830,180 deaths in 2020 (GLOBOCAN). The 5-year survival rate for localized HCC is about 36% (NCI SEER), but drops to 12% for regional and 3% for distant stages. Major risk factors include chronic hepatitis B (HBV) and C (HCV) infections, alcohol-induced cirrhosis, non-alcoholic fatty liver disease (NAFLD), and aflatoxin exposure. The rising incidence of metabolic syndrome and NAFLD is driving HCC cases in Western countries. The high mortality and limited effective therapies underscore the urgent need for better preclinical models to study HCC biology and test novel therapeutics.

HCC is an ideal disease for mechanistic studies due to its well-characterized molecular subtypes, extensive public genomic datasets (TCGA, ICGC), and the availability of numerous cell lines representing different genetic backgrounds. Key open questions include the role of tumor heterogeneity, the interplay between the tumor microenvironment and immune evasion, and the mechanisms of resistance to tyrosine kinase inhibitors (e.g., sorafenib, lenvatinib) and immunotherapies. Gene-edited cell models enable precise dissection of driver mutations and pathway dependencies, facilitating the development of targeted therapies and biomarkers.

HCC development is driven by several key pathways:

• • Wnt/β-catenin pathway: Mutations in CTNNB1 (encoding β-catenin) or loss of APC lead to constitutive activation, promoting cell proliferation and survival.
• • p53 pathway: TP53 mutations (often R249S in aflatoxin-exposed patients) disrupt cell cycle checkpoints and apoptosis.
• • Chromatin remodeling: Mutations in ARID1A, ARID2, and BAP1 alter gene expression and genomic stability.
• • Oxidative stress and inflammation: Chronic liver injury induces reactive oxygen species (ROS) and NF-κB signaling, driving hepatocyte transformation.

These pathways often cooperate to drive tumorigenesis, and their specific mutations define molecular subtypes with distinct clinical outcomes.

Data from TCGA (The Cancer Genome Atlas) and COSMIC (Catalogue of Somatic Mutations in Cancer) reveal recurrent alterations in HCC:

These alterations are critical for tumor initiation and progression, and serve as targets for gene editing.

Beyond the core pathways, several signaling networks are frequently deregulated in HCC:

• • MAPK/ERK pathway: Activated by mutations in RAS (KRAS, NRAS) or upstream receptor tyrosine kinases (EGFR, MET), promoting proliferation.
• • PI3K/AKT/mTOR pathway: PTEN loss or PIK3CA mutations activate this survival pathway.
• • JAK/STAT pathway: Chronic inflammation and IL-6 signaling drive STAT3 activation, supporting tumor growth.
• • Hedgehog pathway: Overexpression of Gli1 and Ptch1 contributes to cancer stem cell maintenance.

These networks provide opportunities for combination therapies and are often targeted in drug discovery.

Common HCC cell lines and their key mutations (based on COSMIC and NCBI Gene):

Organoids derived from patient tumors retain the genetic heterogeneity and 3D architecture, making them valuable for drug testing and personalized medicine. However, they are more complex to culture and less amenable to high-throughput screening.

Animal models are essential for studying HCC in vivo:

• • Patient-derived xenografts (PDX): Implantation of patient tumor tissue into immunodeficient mice; preserves tumor heterogeneity but lacks immune system.
• • Genetically engineered mouse models (GEMM): e.g., Alb-Cre;Trp53^fl/fl mice develop HCC with p53 loss; allow study of tumor initiation and progression.
• • Induced models: Chemical induction with diethylnitrosamine (DEN) or carbon tetrachloride (CCl4) mimics inflammation-driven HCC.
• • Syngeneic models: Implantation of mouse HCC cell lines (e.g., Hepa1-6) into immunocompetent mice to study immune interactions.

These models are useful for validating gene function and testing immunotherapies, but they are time-consuming and costly.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise genetic modifications, such as:

• • TP53 knockout: Abolishes p53 function, mimicking loss-of-function mutations.
• • CTNNB1 knock-in (e.g., S33Y): Constitutively activates Wnt signaling.
• • KRAS G12D knock-in: Activates MAPK pathway.
• • Reporter lines: e.g., GFP-tagged proteins for live-cell imaging.

These models are commercially available and sequence-verified, ensuring reproducibility. They accelerate research by providing clean genetic backgrounds to study gene function, drug response, and resistance mechanisms without confounding factors from patient heterogeneity.

Gene-edited cell lines are used to validate the functional role of candidate driver genes identified from genomic studies. For example:

• • TP53 knockout in HepG2 cells leads to increased proliferation and resistance to apoptosis, confirming its tumor suppressor role.
• • CTNNB1 knock-in in Huh7 cells enhances Wnt signaling and promotes colony formation, demonstrating oncogenic activity.

These models allow researchers to study the impact of specific mutations on cellular phenotypes, such as migration, invasion, and metabolic reprogramming.

Isogenic pairs (wild-type vs. knockout/knock-in) are powerful tools for drug screening:

• • Sensitivity testing: Compare IC50 values of drugs (e.g., sorafenib, lenvatinib) in isogenic pairs to identify mutations that confer resistance or sensitivity.
• • Resistance modeling: Chronic exposure of gene-edited cells to drugs can select for resistant clones, revealing mechanisms of acquired resistance.
• • Combination therapy: Test synergistic effects of drugs targeting different pathways in engineered cells.

For example, TP53-null HCC cells show increased sensitivity to Wee1 inhibitors, suggesting a synthetic lethal approach.

CRISPR-based screens using gene-edited cells can identify novel biomarkers and therapeutic targets:

• • Synthetic lethality screens: Knockout libraries in TP53-mutant cells identify genes essential for survival, such as ATR or CHK1.
• • Reporter lines: Cells with fluorescent reporters (e.g., for Wnt activity) enable high-content screening for pathway modulators.
• • Secretome analysis: Gene-edited cells can be used to identify secreted proteins that serve as diagnostic or prognostic biomarkers.

These approaches accelerate precision medicine by linking genetic alterations to therapeutic vulnerabilities.

Researchers can access extensive HCC data from public databases: